<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="discussion"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 1.1?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Dev Biol</journal-id><journal-id journal-id-type="iso-abbrev">J Dev Biol</journal-id><journal-id journal-id-type="publisher-id">jdb</journal-id><journal-title-group><journal-title>Journal of Developmental Biology</journal-title></journal-title-group><issn pub-type="epub">2221-3759</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">5875559</article-id><article-id pub-id-type="doi">10.3390/jdb6010001</article-id><article-id pub-id-type="publisher-id">jdb-06-00001</article-id><article-categories><subj-group subj-group-type="heading"><subject>Commentary</subject></subj-group></article-categories><title-group><article-title>Modeling Alzheimer&#x02019;s and Other Age Related Human Diseases in Embryonic Systems</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-6691-8277</contrib-id><name><surname>Lim</surname><given-names>Chu Hsien</given-names></name><xref ref-type="aff" rid="af1-jdb-06-00001">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-4591-5274</contrib-id><name><surname>Mathuru</surname><given-names>Ajay S.</given-names></name><xref ref-type="aff" rid="af1-jdb-06-00001">1</xref><xref ref-type="aff" rid="af2-jdb-06-00001">2</xref><xref rid="c1-jdb-06-00001" ref-type="corresp">*</xref></contrib></contrib-group><aff id="af1-jdb-06-00001"><label>1</label>Yale NUS College, 16 College Avenue West, Singapore 138610, Singapore; <email>limchuhsien@yale-nus.edu.sg</email></aff><aff id="af2-jdb-06-00001"><label>2</label>Institute of Molecular and Cell Biology, 61 Biopolis Drive, Singapore 137673, Singapore</aff><author-notes><corresp id="c1-jdb-06-00001"><label>*</label>Correspondence: <email>ajay.mathuru@yale-nus.edu.sg</email></corresp></author-notes><pub-date pub-type="epub"><day>22</day><month>12</month><year>2017</year></pub-date><pub-date pub-type="collection"><month>3</month><year>2018</year></pub-date><volume>6</volume><issue>1</issue><elocation-id>1</elocation-id><history><date date-type="received"><day>22</day><month>11</month><year>2017</year></date><date date-type="accepted"><day>21</day><month>12</month><year>2017</year></date></history><permissions><copyright-statement>&#x000a9; 2017 by the authors.</copyright-statement><copyright-year>2017</copyright-year><license license-type="open-access"><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>Modeling human disease in animals is an important strategy to discover potential methods of intervention. We suggest that there is much to be gained by employing a multi-model approach that takes advantage of different animal systems used in the laboratory simultaneously. We use the example of modeling Alzheimer&#x02019;s disease in <italic>Drosophila melanogaster</italic>, <italic>Caenorhabditis elegans</italic>, and <italic>Danio rerio</italic> to illustrate how such an approach can be employed to investigate the pathophysiology of the disease.</p></abstract><kwd-group><kwd>Alzheimer&#x02019;s disease</kwd><kwd>CRY2</kwd><kwd><italic>Drosophila melanogaster</italic></kwd><kwd><italic>Caenorhabditis elegans</italic></kwd><kwd><italic>Danio rerio</italic></kwd><kwd>optogenetics</kwd></kwd-group></article-meta></front><body><sec id="sec1-jdb-06-00001"><title>1. Introduction</title><p>Animal models are indispensable tools for understanding biology and for designing strategies to mitigate human disease. An important question to address then is the choice of the animal species when modeling a disorder or a disease. After all, animals may not suffer from the same ailments as humans do. A popular idea in the field of neuroethology is to study a &#x02018;champion&#x02019; species or a specialist in the particular motor or sensory function of interest [<xref rid="B1-jdb-06-00001" ref-type="bibr">1</xref>,<xref rid="B2-jdb-06-00001" ref-type="bibr">2</xref>,<xref rid="B3-jdb-06-00001" ref-type="bibr">3</xref>]. An echo-locating bat may reveal the workings of auditory processing or a cephalopod may help us identify a neural mechanism for camouflage. Indeed, unusual insights into cancer pathology have come to us via naked mole rats that are highly resistant to cancers in spite of a life spanning around three decades [<xref rid="B4-jdb-06-00001" ref-type="bibr">4</xref>,<xref rid="B5-jdb-06-00001" ref-type="bibr">5</xref>]. However, this is not entirely suitable to tease apart the molecular and cellular processes underlying disease progression in many cases that often require extensive experimentation and elaborate screens. </p><p>Historically, rodents and non-human primates have received the most attention in medicine as mammalian models, particularly in the final phases of drug or vaccine development prior to clinical trials in humans. However, the costs and infrastructure associated with running such experiments at scale are fast becoming prohibitive. Instead <italic>Drosophila melanogaster</italic>, <italic>Caenorhabditis elegans</italic>, and <italic>Danio rerio</italic> (colloquially, fruit flies, nematode worms, and zebrafish) are increasingly used to study various aspects of diseases for exactly the same reasons that made them popular for studying fundamental biology&#x02014;the ease of rearing them in the lab, performing genetic manipulations, molecular and biochemical analyses, and behavioral studies. For instance, fruit fly, worm, and zebrafish models have been critical to elucidate the RAS signaling pathway in cancer, polyglutamine-expansion disorders, and melanoma respectively among other diseases [<xref rid="B6-jdb-06-00001" ref-type="bibr">6</xref>,<xref rid="B7-jdb-06-00001" ref-type="bibr">7</xref>,<xref rid="B8-jdb-06-00001" ref-type="bibr">8</xref>,<xref rid="B9-jdb-06-00001" ref-type="bibr">9</xref>,<xref rid="B10-jdb-06-00001" ref-type="bibr">10</xref>]. We suggest that using all three in combination may circumvent some of the challenges posed in the search of a &#x02018;champion&#x02019; animal model that satisfactorily recapitulates a disease and allows studies of genetics, physiology, and behavior. In addition, the tools available for studying development in these systems become highly advantageous for dissociating incidental age-related changes from changes causally linked in an age dependent disease.</p></sec><sec id="sec2-jdb-06-00001"><title>2. Alzheimer&#x02019;s Disease: An Unresolved Problem</title><p>In this commentary, we turn our attention to Alzheimer&#x02019;s disease (AD). AD is the most common cause of dementia, and a debilitating age-associated neurodegenerative disease currently lacking effective treatment [<xref rid="B11-jdb-06-00001" ref-type="bibr">11</xref>,<xref rid="B12-jdb-06-00001" ref-type="bibr">12</xref>]. According to a non-profit, voluntary organization specializing in Alzheimer&#x02019;s care, AD is the sixth leading cause of death in America, and there are now 5.5 million Americans living with it [<xref rid="B13-jdb-06-00001" ref-type="bibr">13</xref>]. Globally, there are 46.8 million people living with dementia, including AD and this number is expected to increase to reach 131.5 million people by 2050 [<xref rid="B14-jdb-06-00001" ref-type="bibr">14</xref>]. Global burden of disease studies suggest that the cost of AD and other dementia-related illness is in the range of USD 250 billion in America, and over USD 600 billion globally [<xref rid="B13-jdb-06-00001" ref-type="bibr">13</xref>,<xref rid="B15-jdb-06-00001" ref-type="bibr">15</xref>]. Such statistics highlight the prevalence of AD and other dementia-related illnesses and the grave public health challenge that future generations face. </p><p>Even after several decades of research, the exact cause of AD is yet to be clearly established. However, two classic neuropathological signs are associated with the disease. Namely, neurofibrillary tangles and extracellular Amyloid-&#x003b2; (A&#x003b2;) plaques in the human brain [<xref rid="B16-jdb-06-00001" ref-type="bibr">16</xref>,<xref rid="B17-jdb-06-00001" ref-type="bibr">17</xref>]. Tangles are thought to be caused by misfolding and hyperphosphorylation of tau proteins normally involved in microtubule stabilization [<xref rid="B17-jdb-06-00001" ref-type="bibr">17</xref>]. Plaques, on the other hand, are aggregates of the beta-amyloid peptide&#x02014;a cleavage product of a protein that is normally expressed throughout the ubiquitously called the amyloid precursor protein (APP) [<xref rid="B18-jdb-06-00001" ref-type="bibr">18</xref>]. </p><p>While both these processes are associated with AD, here, for the purpose of illustration, we only consider the amyloid hypothesis. According to this hypothesis, the accumulation of A&#x003b2; in various forms, as plaques or as soluble oligomers cause neuronal damage and the consequent inflammatory response that eventually leads to the deleterious symptoms associated with AD [<xref rid="B19-jdb-06-00001" ref-type="bibr">19</xref>]. Evidence underpinning this association comes from familial cases of early-onset AD, which is linked to germline mutations in APP [<xref rid="B20-jdb-06-00001" ref-type="bibr">20</xref>] and the presenilin genes involved in cleaving A&#x003b2; from APP [<xref rid="B21-jdb-06-00001" ref-type="bibr">21</xref>]. The amyloid hypothesis proponents use pathological similarities between familial and sporadic AD as an argument, as well as observations of other age-related diseases such as the myositis-like phenotype caused by A&#x003b2; accumulation in transgenic mice overexpressing A&#x003b2; in muscle tissue [<xref rid="B22-jdb-06-00001" ref-type="bibr">22</xref>]. </p><p>Despite such evidence, the pathophysiology of A&#x003b2; plaques and their relation to AD is not a settled issue. Critics of the amyloid hypothesis point out findings of A&#x003b2; plaques in brains of individuals who did not show any symptoms of AD at the time of death. Other unresolved issues including poor correlation between plaque load and cognitive scores and heterogeneity in pathology have called into question the causal association ascribed to A&#x003b2; plaques [<xref rid="B23-jdb-06-00001" ref-type="bibr">23</xref>]. There has been a shift of focus from plaques to the other potential malfunctions including to role of soluble forms of A&#x003b2; oligomerisation that further triggers a downstream cascade [<xref rid="B24-jdb-06-00001" ref-type="bibr">24</xref>]. A recent paper also demonstrated that blood-derived A&#x003b2; resulted in pathogenic symptoms of AD in mice models, suggesting that A&#x003b2; plaques need not originate in the brain to evoke pathological symptoms [<xref rid="B25-jdb-06-00001" ref-type="bibr">25</xref>]. Given the current status, whether extracellular A&#x003b2; plaques have a detrimental role in AD, or if they have a protective role before other malfunctions accumulate continues to be a central question [<xref rid="B26-jdb-06-00001" ref-type="bibr">26</xref>]. Further, even though extracellular plaques are considered a hallmark of AD, consensus on whether problems arise due to A&#x003b2; aggregates formed intracellularly in neurons, or from secreted peptides extracellulary (or either), is also lacking [<xref rid="B27-jdb-06-00001" ref-type="bibr">27</xref>,<xref rid="B28-jdb-06-00001" ref-type="bibr">28</xref>,<xref rid="B29-jdb-06-00001" ref-type="bibr">29</xref>].</p></sec><sec id="sec3-jdb-06-00001"><title>3. Combining Forces</title><p>To unravel these questions, one approach could be to first clearly evaluate if A&#x003b2; plaque formation has any impact on neuronal health and cognitive performance. One approach is to use a multi-model study design that capitalizes on the unique advantages of flies, nematodes, and zebrafish.</p><p>Research using <italic>Drosophila</italic> has been vital to dissect genetic pathways critical for the formation, migration, and activity of A&#x003b2; plaques [<xref rid="B6-jdb-06-00001" ref-type="bibr">6</xref>]. Using the galactose-inducible yeast system, commonly known as the Gal4/UAS system [<xref rid="B30-jdb-06-00001" ref-type="bibr">30</xref>], transgenic flies can be easily generated to analyze several genetic pathways in a short period. The genetic pathways identified from such analyses can be further investigated in <italic>C. elegans</italic> biochemically. <italic>C. elegans</italic> has been widely employed to investigate the effects of aging and various neurodegenerative diseases, including AD [<xref rid="B7-jdb-06-00001" ref-type="bibr">7</xref>]. With a short life cycle of three days from egg to adult, they are highly amenable to evaluate the &#x0201c;druggability&#x0201d; of targets among the biochemical pathways [<xref rid="B31-jdb-06-00001" ref-type="bibr">31</xref>]. Feeding assays can be designed to implement large-scale drug screens or screens based on RNA interference (RNAi) knockdown [<xref rid="B7-jdb-06-00001" ref-type="bibr">7</xref>]. Another factor when modeling human pathologies is to recapitulate the biological outcomes described in humans. Compared to the two invertebrate animal models, the vertebrate nervous system of zebrafish is more appropriate to study the consequences of A&#x003b2; plaques in the brain. Due to their transparent nature, zebrafish are also an excellent tool to investigate neural activity in vivo, thereby making them particularly useful when studying neurophysiology. Using whole brain imaging and cell-type specific labeling techniques, unique neurons in any region of the brain can be studied with ease [<xref rid="B32-jdb-06-00001" ref-type="bibr">32</xref>]. In addition, several behavioral paradigms have already been developed that can be employed to evaluate the cognitive impact if neurodegeneration is occurring [<xref rid="B33-jdb-06-00001" ref-type="bibr">33</xref>].</p><p>Advancements in imaging and genetic techniques further enhance the utility of this multi-model approach. One such technique is optogenetics&#x02014;an extremely versatile tool using light to examine physiological processes [<xref rid="B34-jdb-06-00001" ref-type="bibr">34</xref>]. Compared to the constraints posed by electrical recordings and pharmacological interventions in the past, optogenetics can be used to examine specific cellular activities with extremely high precision and speed in vivo. Recently, cryptochrome2 (CRY2) protein system from the <italic>Arabidopsis</italic> was modified as an optogenetic tool to study the control of cortical actin dynamics in cell culture and cell contractility during tissue morphogenesis in <italic>Drosophila</italic> embryos [<xref rid="B35-jdb-06-00001" ref-type="bibr">35</xref>,<xref rid="B36-jdb-06-00001" ref-type="bibr">36</xref>]. Activation of the CRY2 oligomerization at 488 nm and inhibition in the dark allows researchers to manipulate protein&#x02013;protein interactions without the need for other external agents [<xref rid="B37-jdb-06-00001" ref-type="bibr">37</xref>]. </p><p>It is not hard to imagine that the same CRY2 optogenetic system can be employed with A&#x003b2; to create an in vivo, light-dependent, oligomerization switch for the formation or dissolution of A&#x003b2; aggregates (<xref ref-type="fig" rid="jdb-06-00001-f001">Figure 1</xref>). By generating transgenics in all three organisms in the neurons, or cells of interest, the spatiotemporal kinetics of A&#x003b2; plaque formation can be controlled at will to address the question of their relationship and AD pathogenesis. Light-inducible aggregates in worms will allow fast screening for drugs that are effective in dissolution when administered before, or after, or when plaques form repeatedly. Transparency of zebrafish allows imaging the kinetics of plaque formation. We envisage that the use of such a technique in fish will also shed light on the link between intracellular A&#x003b2; peptide aggregates and extracellular plaques. In addition, promising drugs screened in the worm studies can be rapidly evaluated in the context of a vertebrate brain. A battery of behavioral assays reporting on learning, memory, anxiety, and depression can then be employed to assess the impact [<xref rid="B33-jdb-06-00001" ref-type="bibr">33</xref>]. Finally, flies that express A&#x003b2; CRY2 in specific organs, at specific times, will be highly informative to understand the spatiotemporal dynamics of plaque location for any pathogenic effect to be visible, as well as to identify genetic interactors at different stages in case pathogenicity is observed [<xref rid="B25-jdb-06-00001" ref-type="bibr">25</xref>]. Together, these will likely provide firm answers to the questions raised by the amyloid hypothesis of AD, especially on the role of soluble vs. A&#x003b2; plaques as plaque formation can be engineered externally.</p><p>The potential of using such a combinatory approach of various model organisms and optogenetics is therefore vast, can be applied to other diseases and will only continue to expand as further improvements in technology become available.</p></sec></body><back><ack><title>Acknowledgments</title><p>We thank the two anonymous reviewers and Nicholas Tolwinski for comments. This work was supported by Yale-NUS College through grants R-607-265-225-121 and IG16-LR003; and by Agency for Science, Technology and Research (A*STAR).</p></ack><notes><title>Author Contributions</title><p>C.H.L and A.S.M wrote the manuscript.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflict of interest.</p></notes><ref-list><title>References</title><ref id="B1-jdb-06-00001"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bullock</surname><given-names>T.H.</given-names></name></person-group><article-title>Comparative neuroscience holds promise for quiet revolutions</article-title><source>Science</source><year>1984</year><volume>225</volume><fpage>473</fpage><lpage>478</lpage><pub-id pub-id-type="doi">10.1126/science.6740319</pub-id><?supplied-pmid 6740319?><pub-id pub-id-type="pmid">6740319</pub-id></element-citation></ref><ref id="B2-jdb-06-00001"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bullock</surname><given-names>T.H.</given-names></name></person-group><article-title>&#x0201c;Simple&#x0201d; model systems need comparative studies: Differences are as important as commonalities</article-title><source>Trends Neurosci.</source><year>1986</year><volume>9</volume><fpage>470</fpage><lpage>472</lpage><pub-id pub-id-type="doi">10.1016/0166-2236(86)90151-7</pub-id></element-citation></ref><ref id="B3-jdb-06-00001"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heiligenberg</surname><given-names>W.</given-names></name></person-group><article-title>The neural basis of behavior: A neuroethological view</article-title><source>Annu. Rev. Neurosci.</source><year>1991</year><volume>14</volume><fpage>247</fpage><lpage>267</lpage><pub-id pub-id-type="doi">10.1146/annurev.ne.14.030191.001335</pub-id><?supplied-pmid 2031571?><pub-id pub-id-type="pmid">2031571</pub-id></element-citation></ref><ref id="B4-jdb-06-00001"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tian</surname><given-names>X.</given-names></name><name><surname>Azpurua</surname><given-names>J.</given-names></name><name><surname>Hine</surname><given-names>C.</given-names></name><name><surname>Vaidya</surname><given-names>A.</given-names></name><name><surname>Myakishev-Rempel</surname><given-names>M.</given-names></name><name><surname>Ablaeva</surname><given-names>J.</given-names></name><name><surname>Mao</surname><given-names>Z.</given-names></name><name><surname>Nevo</surname><given-names>E.</given-names></name><name><surname>Gorbunova</surname><given-names>V.</given-names></name><name><surname>Seluanov</surname><given-names>A.</given-names></name></person-group><article-title>High-molecular-mass hyaluronan mediates the cancer resistance of the naked mole rat</article-title><source>Nature</source><year>2013</year><volume>499</volume><fpage>346</fpage><pub-id pub-id-type="doi">10.1038/nature12234</pub-id><?supplied-pmid 23783513?><pub-id pub-id-type="pmid">23783513</pub-id></element-citation></ref><ref id="B5-jdb-06-00001"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Delaney</surname><given-names>M.A.</given-names></name><name><surname>Ward</surname><given-names>J.M.</given-names></name><name><surname>Walsh</surname><given-names>T.F.</given-names></name><name><surname>Chinnadurai</surname><given-names>S.K.</given-names></name><name><surname>Kerns</surname><given-names>K.</given-names></name><name><surname>Kinsel</surname><given-names>M.J.</given-names></name><name><surname>Treuting</surname><given-names>P.M.</given-names></name></person-group><article-title>Initial case reports of cancer in naked mole-rats (heterocephalus glaber)</article-title><source>Vet. Pathol.</source><year>2016</year><volume>53</volume><fpage>691</fpage><lpage>696</lpage><pub-id pub-id-type="doi">10.1177/0300985816630796</pub-id><?supplied-pmid 26846576?><pub-id pub-id-type="pmid">26846576</pub-id></element-citation></ref><ref id="B6-jdb-06-00001"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pandey</surname><given-names>U.B.</given-names></name><name><surname>Nichols</surname><given-names>C.D.</given-names></name></person-group><article-title>Human disease models in drosophila melanogaster and the role of the fly in therapeutic drug discovery</article-title><source>Pharmacol. Rev.</source><year>2011</year><volume>63</volume><fpage>411</fpage><lpage>436</lpage><pub-id pub-id-type="doi">10.1124/pr.110.003293</pub-id><?supplied-pmid 21415126?><pub-id pub-id-type="pmid">21415126</pub-id></element-citation></ref><ref id="B7-jdb-06-00001"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Markaki</surname><given-names>M.</given-names></name><name><surname>Tavernarakis</surname><given-names>N.</given-names></name></person-group><article-title>Modeling human diseases in caenorhabditis elegans</article-title><source>Biotechnol. J.</source><year>2010</year><volume>5</volume><fpage>1261</fpage><lpage>1276</lpage><pub-id pub-id-type="doi">10.1002/biot.201000183</pub-id><?supplied-pmid 21154667?><pub-id pub-id-type="pmid">21154667</pub-id></element-citation></ref><ref id="B8-jdb-06-00001"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Santoriello</surname><given-names>C.</given-names></name><name><surname>Zon</surname><given-names>L.I.</given-names></name></person-group><article-title>Hooked! Modeling human disease in zebrafish</article-title><source>J. Clin. Investig.</source><year>2012</year><volume>122</volume><fpage>2337</fpage><lpage>2343</lpage><pub-id pub-id-type="doi">10.1172/JCI60434</pub-id><?supplied-pmid 22751109?><pub-id pub-id-type="pmid">22751109</pub-id></element-citation></ref><ref id="B9-jdb-06-00001"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moulton</surname><given-names>M.J.</given-names></name><name><surname>Letsou</surname><given-names>A.</given-names></name></person-group><article-title>Modeling congenital disease and inborn errors of development in drosophila melanogaster</article-title><source>Dis. Models Mech.</source><year>2016</year><volume>9</volume><fpage>253</fpage><lpage>269</lpage><pub-id pub-id-type="doi">10.1242/dmm.023564</pub-id><?supplied-pmid 26935104?><pub-id pub-id-type="pmid">26935104</pub-id></element-citation></ref><ref id="B10-jdb-06-00001"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kessler</surname><given-names>M.</given-names></name><name><surname>Rottbauer</surname><given-names>W.</given-names></name><name><surname>Just</surname><given-names>S.</given-names></name></person-group><article-title>Recent progress in the use of zebrafish for novel cardiac drug discovery</article-title><source>Expert Opin. Drug Discov.</source><year>2015</year><volume>10</volume><fpage>1231</fpage><lpage>1241</lpage><pub-id pub-id-type="doi">10.1517/17460441.2015.1078788</pub-id><?supplied-pmid 26294375?><pub-id pub-id-type="pmid">26294375</pub-id></element-citation></ref><ref id="B11-jdb-06-00001"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumar</surname><given-names>A.</given-names></name><name><surname>Singh</surname><given-names>A.</given-names></name><name><surname>Ekavali</surname></name></person-group><article-title>A review on alzheimer&#x02019;s disease pathophysiology and its management: An update</article-title><source>Pharmacol. Rep.</source><year>2015</year><volume>67</volume><fpage>195</fpage><lpage>203</lpage><pub-id pub-id-type="doi">10.1016/j.pharep.2014.09.004</pub-id><?supplied-pmid 25712639?><pub-id pub-id-type="pmid">25712639</pub-id></element-citation></ref><ref id="B12-jdb-06-00001"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De-Paula</surname><given-names>V.J.</given-names></name><name><surname>Radanovic</surname><given-names>M.</given-names></name><name><surname>Diniz</surname><given-names>B.S.</given-names></name><name><surname>Forlenza</surname><given-names>O.V.</given-names></name></person-group><article-title>Alzheimer&#x02019;s disease</article-title><source>Sub-Cell. Biochem.</source><year>2012</year><volume>65</volume><fpage>329</fpage><lpage>352</lpage></element-citation></ref><ref id="B13-jdb-06-00001"><label>13.</label><element-citation publication-type="web"><person-group person-group-type="author"><collab>Alzheimer&#x02019;s Association</collab></person-group><article-title>2017 Alzheimer&#x02019;s Disease Facts and Figures</article-title><comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://www.alz.org/documents_custom/2017-facts-and-figures.pdf">https://www.alz.org/documents_custom/2017-facts-and-figures.pdf</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2017-11-10">(accessed on 10 November 2017)</date-in-citation></element-citation></ref><ref id="B14-jdb-06-00001"><label>14.</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>Alzheimer&#x02019;s Disease International</collab></person-group><source>World Alzheimer Report 2016: Improving Healthcare for People Living with Dementia</source><publisher-name>Alzheimer&#x02019;s Disease International (ADI)</publisher-name><publisher-loc>London, UK</publisher-loc><year>2016</year></element-citation></ref><ref id="B15-jdb-06-00001"><label>15.</label><element-citation publication-type="web"><person-group person-group-type="author"><collab>Alzheimers.net</collab></person-group><article-title>2016 Alzheimer&#x02019;s Statistics</article-title><comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://www.alzheimers.net/resources/alzheimers-statistics/">https://www.alzheimers.net/resources/alzheimers-statistics/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2017-11-10">(accessed on 10 November 2017)</date-in-citation></element-citation></ref><ref id="B16-jdb-06-00001"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alexander</surname><given-names>A.G.</given-names></name><name><surname>Marfil</surname><given-names>V.</given-names></name><name><surname>Li</surname><given-names>C.</given-names></name></person-group><article-title>Use of caenorhabditis elegans as a model to study alzheimer&#x02019;s disease and other neurodegenerative diseases</article-title><source>Front. Genet.</source><year>2014</year><volume>5</volume><fpage>279</fpage><pub-id pub-id-type="doi">10.3389/fgene.2014.00279</pub-id><?supplied-pmid 25250042?><pub-id pub-id-type="pmid">25250042</pub-id></element-citation></ref><ref id="B17-jdb-06-00001"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iqbal</surname><given-names>K.</given-names></name><name><surname>Alonso Adel</surname><given-names>C.</given-names></name><name><surname>Chen</surname><given-names>S.</given-names></name><name><surname>Chohan</surname><given-names>M.O.</given-names></name><name><surname>El-Akkad</surname><given-names>E.</given-names></name><name><surname>Gong</surname><given-names>C.X.</given-names></name><name><surname>Khatoon</surname><given-names>S.</given-names></name><name><surname>Li</surname><given-names>B.</given-names></name><name><surname>Liu</surname><given-names>F.</given-names></name><name><surname>Rahman</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Tau pathology in alzheimer disease and other tauopathies</article-title><source>Biochim. Biophys. Acta</source><year>2005</year><volume>1739</volume><fpage>198</fpage><lpage>210</lpage><pub-id pub-id-type="doi">10.1016/j.bbadis.2004.09.008</pub-id><?supplied-pmid 15615638?><pub-id pub-id-type="pmid">15615638</pub-id></element-citation></ref><ref id="B18-jdb-06-00001"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kang</surname><given-names>J.</given-names></name><name><surname>Lemaire</surname><given-names>H.G.</given-names></name><name><surname>Unterbeck</surname><given-names>A.</given-names></name><name><surname>Salbaum</surname><given-names>J.M.</given-names></name><name><surname>Masters</surname><given-names>C.L.</given-names></name><name><surname>Grzeschik</surname><given-names>K.H.</given-names></name><name><surname>Multhaup</surname><given-names>G.</given-names></name><name><surname>Beyreuther</surname><given-names>K.</given-names></name><name><surname>Muller-Hill</surname><given-names>B.</given-names></name></person-group><article-title>The precursor of alzheimer&#x02019;s disease amyloid a4 protein resembles a cell-surface receptor</article-title><source>Nature</source><year>1987</year><volume>325</volume><fpage>733</fpage><lpage>736</lpage><pub-id pub-id-type="doi">10.1038/325733a0</pub-id><?supplied-pmid 2881207?><pub-id pub-id-type="pmid">2881207</pub-id></element-citation></ref><ref id="B19-jdb-06-00001"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eskelinen</surname><given-names>M.H.</given-names></name><name><surname>Kivipelto</surname><given-names>M.</given-names></name></person-group><article-title>Caffeine as a protective factor in dementia and alzheimer&#x02019;s disease</article-title><source>J. Alzheimer&#x02019;s Dis. JAD</source><year>2010</year><volume>20</volume><issue>Suppl. 1</issue><fpage>S167</fpage><lpage>S174</lpage><pub-id pub-id-type="doi">10.3233/JAD-2010-1404</pub-id><?supplied-pmid 20182054?><pub-id pub-id-type="pmid">20182054</pub-id></element-citation></ref><ref id="B20-jdb-06-00001"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chartier-Harlin</surname><given-names>M.C.</given-names></name><name><surname>Crawford</surname><given-names>F.</given-names></name><name><surname>Houlden</surname><given-names>H.</given-names></name><name><surname>Warren</surname><given-names>A.</given-names></name><name><surname>Hughes</surname><given-names>D.</given-names></name><name><surname>Fidani</surname><given-names>L.</given-names></name><name><surname>Goate</surname><given-names>A.</given-names></name><name><surname>Rossor</surname><given-names>M.</given-names></name><name><surname>Roques</surname><given-names>P.</given-names></name><name><surname>Hardy</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Early-onset alzheimer&#x02019;s disease caused by mutations at codon 717 of the beta-amyloid precursor protein gene</article-title><source>Nature</source><year>1991</year><volume>353</volume><fpage>844</fpage><lpage>846</lpage><pub-id pub-id-type="doi">10.1038/353844a0</pub-id><?supplied-pmid 1944558?><pub-id pub-id-type="pmid">1944558</pub-id></element-citation></ref><ref id="B21-jdb-06-00001"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cruts</surname><given-names>M.</given-names></name><name><surname>Hendriks</surname><given-names>L.</given-names></name><name><surname>Van Broeckhoven</surname><given-names>C.</given-names></name></person-group><article-title>The presenilin genes: A new gene family involved in alzheimer disease pathology</article-title><source>Hum. Mol. Genet.</source><year>1996</year><volume>5</volume><fpage>1449</fpage><lpage>1455</lpage><pub-id pub-id-type="doi">10.1093/hmg/5.Supplement_1.1449</pub-id><?supplied-pmid 8875251?><pub-id pub-id-type="pmid">8875251</pub-id></element-citation></ref><ref id="B22-jdb-06-00001"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sugarman</surname><given-names>M.C.</given-names></name><name><surname>Yamasaki</surname><given-names>T.R.</given-names></name><name><surname>Oddo</surname><given-names>S.</given-names></name><name><surname>Echegoyen</surname><given-names>J.C.</given-names></name><name><surname>Murphy</surname><given-names>M.P.</given-names></name><name><surname>Golde</surname><given-names>T.E.</given-names></name><name><surname>Jannatipour</surname><given-names>M.</given-names></name><name><surname>Leissring</surname><given-names>M.A.</given-names></name><name><surname>LaFerla</surname><given-names>F.M.</given-names></name></person-group><article-title>Inclusion body myositis-like phenotype induced by transgenic overexpression of beta app in skeletal muscle</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2002</year><volume>99</volume><fpage>6334</fpage><lpage>6339</lpage><pub-id pub-id-type="doi">10.1073/pnas.082545599</pub-id><?supplied-pmid 11972038?><pub-id pub-id-type="pmid">11972038</pub-id></element-citation></ref><ref id="B23-jdb-06-00001"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morris</surname><given-names>G.P.</given-names></name><name><surname>Clark</surname><given-names>I.A.</given-names></name><name><surname>Vissel</surname><given-names>B.</given-names></name></person-group><article-title>Inconsistencies and controversies surrounding the amyloid hypothesis of alzheimer&#x02019;s disease</article-title><source>Acta Neuropathol. Commun.</source><year>2014</year><volume>2</volume><fpage>135</fpage><pub-id pub-id-type="doi">10.1186/s40478-014-0135-5</pub-id><?supplied-pmid 25231068?><pub-id pub-id-type="pmid">25231068</pub-id></element-citation></ref><ref id="B24-jdb-06-00001"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Joshi</surname><given-names>P.</given-names></name><name><surname>Turola</surname><given-names>E.</given-names></name><name><surname>Ruiz</surname><given-names>A.</given-names></name><name><surname>Bergami</surname><given-names>A.</given-names></name><name><surname>Libera</surname><given-names>D.D.</given-names></name><name><surname>Benussi</surname><given-names>L.</given-names></name><name><surname>Giussani</surname><given-names>P.</given-names></name><name><surname>Magnani</surname><given-names>G.</given-names></name><name><surname>Comi</surname><given-names>G.</given-names></name><name><surname>Legname</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Microglia convert aggregated amyloid-beta into neurotoxic forms through the shedding of microvesicles</article-title><source>Cell Death Differ.</source><year>2014</year><volume>21</volume><fpage>582</fpage><lpage>593</lpage><pub-id pub-id-type="doi">10.1038/cdd.2013.180</pub-id><?supplied-pmid 24336048?><pub-id pub-id-type="pmid">24336048</pub-id></element-citation></ref><ref id="B25-jdb-06-00001"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bu</surname><given-names>X.L.</given-names></name><name><surname>Xiang</surname><given-names>Y.</given-names></name><name><surname>Jin</surname><given-names>W.S.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Shen</surname><given-names>L.L.</given-names></name><name><surname>Huang</surname><given-names>Z.L.</given-names></name><name><surname>Zhang</surname><given-names>K.</given-names></name><name><surname>Liu</surname><given-names>Y.H.</given-names></name><name><surname>Zeng</surname><given-names>F.</given-names></name><name><surname>Liu</surname><given-names>J.H.</given-names></name><etal/></person-group><article-title>Blood-derived amyloid-&#x003b2; protein induces alzheimer&#x02019;s disease pathologies</article-title><source>Mol. Psychiatry</source><year>2017</year><pub-id pub-id-type="doi">10.1038/mp.2017.204</pub-id><?supplied-pmid 29086767?><pub-id pub-id-type="pmid">29086767</pub-id></element-citation></ref><ref id="B26-jdb-06-00001"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>S.</given-names></name><name><surname>Mims</surname><given-names>P.N.</given-names></name><name><surname>Roman</surname><given-names>R.J.</given-names></name><name><surname>Fan</surname><given-names>F.</given-names></name></person-group><article-title>Is beta-amyloid accumulation a cause or consequence of alzheimer&#x02019;s disease?</article-title><source>J. Alzheimer&#x02019;s Parkinsonism Dement.</source><year>2016</year><volume>1</volume><fpage>007</fpage><pub-id pub-id-type="pmid">28815226</pub-id></element-citation></ref><ref id="B27-jdb-06-00001"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Friedrich</surname><given-names>R.P.</given-names></name><name><surname>Tepper</surname><given-names>K.</given-names></name><name><surname>R&#x000f6;nicke</surname><given-names>R.</given-names></name><name><surname>Soom</surname><given-names>M.</given-names></name><name><surname>Westermann</surname><given-names>M.</given-names></name><name><surname>Reymann</surname><given-names>K.</given-names></name><name><surname>Kaether</surname><given-names>C.</given-names></name><name><surname>F&#x000e4;ndrich</surname><given-names>M.</given-names></name></person-group><article-title>Mechanism of amyloid plaque formation suggests an intracellular basis of a&#x003b2; pathogenicity</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2010</year><volume>107</volume><fpage>1942</fpage><lpage>1947</lpage><pub-id pub-id-type="doi">10.1073/pnas.0904532106</pub-id><?supplied-pmid 20133839?><pub-id pub-id-type="pmid">20133839</pub-id></element-citation></ref><ref id="B28-jdb-06-00001"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gouras</surname><given-names>G.K.</given-names></name><name><surname>Tampellini</surname><given-names>D.</given-names></name><name><surname>Takahashi</surname><given-names>R.H.</given-names></name><name><surname>Capetillo-Zarate</surname><given-names>E.</given-names></name></person-group><article-title>Intraneuronal &#x003b2;-amyloid accumulation and synapse pathology in alzheimer&#x02019;s disease</article-title><source>Acta Neuropathol.</source><year>2010</year><volume>119</volume><fpage>523</fpage><lpage>541</lpage><pub-id pub-id-type="doi">10.1007/s00401-010-0679-9</pub-id><?supplied-pmid 20354705?><pub-id pub-id-type="pmid">20354705</pub-id></element-citation></ref><ref id="B29-jdb-06-00001"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y.-W.</given-names></name><name><surname>Thompson</surname><given-names>R.</given-names></name><name><surname>Zhang</surname><given-names>H.</given-names></name><name><surname>Xu</surname><given-names>H.</given-names></name></person-group><article-title>App processing in alzheimer&#x02019;s disease</article-title><source>Mol. Brain</source><year>2011</year><volume>4</volume><fpage>3</fpage><pub-id pub-id-type="doi">10.1186/1756-6606-4-3</pub-id><?supplied-pmid 21214928?><pub-id pub-id-type="pmid">21214928</pub-id></element-citation></ref><ref id="B30-jdb-06-00001"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duffy</surname><given-names>J.B.</given-names></name></person-group><article-title>Gal4 system in drosophila: A fly geneticist&#x02019;s swiss army knife</article-title><source>Genesis</source><year>2002</year><volume>34</volume><fpage>1</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1002/gene.10150</pub-id><?supplied-pmid 12324939?><pub-id pub-id-type="pmid">12324939</pub-id></element-citation></ref><ref id="B31-jdb-06-00001"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brenner</surname><given-names>S.</given-names></name></person-group><article-title>The genetics of caenorhabditis elegans</article-title><source>Genetics</source><year>1974</year><volume>77</volume><fpage>71</fpage><lpage>94</lpage><?supplied-pmid 4366476?><pub-id pub-id-type="pmid">4366476</pub-id></element-citation></ref><ref id="B32-jdb-06-00001"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kawashima</surname><given-names>T.</given-names></name><name><surname>Zwart</surname><given-names>M.F.</given-names></name><name><surname>Yang</surname><given-names>C.T.</given-names></name><name><surname>Mensh</surname><given-names>B.D.</given-names></name><name><surname>Ahrens</surname><given-names>M.B.</given-names></name></person-group><article-title>The serotonergic system tracks the outcomes of actions to mediate short-term motor learning</article-title><source>Cell</source><year>2016</year><volume>167</volume><fpage>933</fpage><lpage>946</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2016.09.055</pub-id><?supplied-pmid 27881303?><pub-id pub-id-type="pmid">27881303</pub-id></element-citation></ref><ref id="B33-jdb-06-00001"><label>33.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Edward</surname><given-names>D.</given-names></name><name><surname>Levin</surname><given-names>D.T.C.</given-names></name></person-group><source>Methods of Behavior Analysis in Neuroscience</source><edition>2 ed.</edition><publisher-name>CRC Press/Taylor &#x00026; Francis</publisher-name><publisher-loc>Boca Raton, FL, USA</publisher-loc><year>2009</year></element-citation></ref><ref id="B34-jdb-06-00001"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fenno</surname><given-names>L.</given-names></name><name><surname>Yizhar</surname><given-names>O.</given-names></name><name><surname>Deisseroth</surname><given-names>K.</given-names></name></person-group><article-title>The development and application of optogenetics</article-title><source>Annu. Rev. Neurosci.</source><year>2011</year><volume>34</volume><fpage>389</fpage><lpage>412</lpage><pub-id pub-id-type="doi">10.1146/annurev-neuro-061010-113817</pub-id><?supplied-pmid 21692661?><pub-id pub-id-type="pmid">21692661</pub-id></element-citation></ref><ref id="B35-jdb-06-00001"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guglielmi</surname><given-names>G.</given-names></name><name><surname>Barry</surname><given-names>J.D.</given-names></name><name><surname>Huber</surname><given-names>W.</given-names></name><name><surname>De Renzis</surname><given-names>S.</given-names></name></person-group><article-title>An optogenetic method to modulate cell contractility during tissue morphogenesis</article-title><source>Dev. Cell</source><year>2015</year><volume>35</volume><fpage>646</fpage><lpage>660</lpage><pub-id pub-id-type="doi">10.1016/j.devcel.2015.10.020</pub-id><?supplied-pmid 26777292?><pub-id pub-id-type="pmid">26777292</pub-id></element-citation></ref><ref id="B36-jdb-06-00001"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Idevall-Hagren</surname><given-names>O.</given-names></name><name><surname>Dickson</surname><given-names>E.J.</given-names></name><name><surname>Hille</surname><given-names>B.</given-names></name><name><surname>Toomre</surname><given-names>D.K.</given-names></name><name><surname>De Camilli</surname><given-names>P.</given-names></name></person-group><article-title>Optogenetic control of phosphoinositide metabolism</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2012</year><volume>109</volume><fpage>E2316</fpage><lpage>E2323</lpage><pub-id pub-id-type="doi">10.1073/pnas.1211305109</pub-id><?supplied-pmid 22847441?><pub-id pub-id-type="pmid">22847441</pub-id></element-citation></ref><ref id="B37-jdb-06-00001"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kennedy</surname><given-names>M.J.</given-names></name><name><surname>Hughes</surname><given-names>R.M.</given-names></name><name><surname>Peteya</surname><given-names>L.A.</given-names></name><name><surname>Schwartz</surname><given-names>J.W.</given-names></name><name><surname>Ehlers</surname><given-names>M.D.</given-names></name><name><surname>Tucker</surname><given-names>C.L.</given-names></name></person-group><article-title>Rapid blue-light-mediated induction of protein interactions in living cells</article-title><source>Nat. Methods</source><year>2010</year><volume>7</volume><fpage>973</fpage><lpage>975</lpage><pub-id pub-id-type="doi">10.1038/nmeth.1524</pub-id><?supplied-pmid 21037589?><pub-id pub-id-type="pmid">21037589</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="jdb-06-00001-f001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>A&#x003b2; CRY2 optogenetic system. The schematic shows an example of in vivo, light-dependent, oligomerization switch for the formation or dissolution of A&#x003b2; aggregates in region of interest (neurons) in a transgenic zebrafish.</p></caption><graphic xlink:href="jdb-06-00001-g001"/></fig></floats-group></article>